Zydus Lifesciences’ arm inks pact with PRG S&T to license molecule for HGPS

17 Mar 2026 Evaluate

Zydus Lifesciences’ wholly-owned subsidiary -- Sentynl Therapeutics Inc. (Sentynl), a U.S.-based biopharmaceutical company, has entered into an agreement with PRG S&T, a Korean company specializing in the development of medicine for rare genetic diseases, to license its investigational molecule Progerinin (SLC-D011) for Hutchinson-Gilford Progeria Syndrome (HGPS or progeria).

The agreement will allow Sentynl to begin working with PRG S&T immediately to advance the clinical development of Progerinin for HGPS, which has been designated as an orphan drug by the United States Food and Drug Administration (FDA). Under the conditions that certain steps are met, Sentynl will acquire full rights to the molecule for HGPS upon closing, making Progerinin the company’s second therapy intended for the treatment of HGPS. The program is currently finalizing a Phase 2A clinical trial and data are expected before the end of 1H 2026.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

890.60 14.25 (1.63%)
20-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.45
Dr. Reddys Lab 1298.95
Cipla 1255.85
Zydus Lifesciences 890.60
Lupin 2322.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×